stockrow
Friday 6 November 2026
Export HCM’s income statement to Excel — free account
HUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
14.27
0.35
+2.51%
Follow HCM
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 3 | 7 | 3 | 3 | 4 | 2 | 3 | 3 | 4 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
3.53 | 3.06 | 3.84 | 2.18 | 9.65 | 12.30 | 12.21 | 15.34 | 26.36 | 7.13 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
6.45 | 2.80 | 2.89 | (0.94) | 4.52 | 2.33 | 0.89 | 4.83 | 6.92 | 1.25 |
Beneish M-Score |
(1.20) | (1.67) | (2.86) | (2.84) | (1.99) | (2.47) | (2.57) | (2.91) | (2.51) | (1.71) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(0.13) | (0.07) | (0.08) | (0.10) | (0.19) | (0.15) | (0.06) | (0.11) | 0.00 | 0.00 |
EV/EBITDA |
0.38 | 0.23 | 0.24 | 0.12 | 0.35 | 0.21 | 0.11 | 0.28 | 0.00 | 0.00 |
EV/Operating CF |
7.20 | 8.35 | (9.25) | 0.91 | 1.04 | 3.27 | 1.35 | 6.60 | (32.91) | 5.75 |
EV/FCF |
5.58 | 4.30 | 36.37 | 0.81 | 0.96 | 2.63 | 1.19 | 4.71 | 81.97 | 2.98 |
Quick Ratio |
4.80 | 2.68 | 2.53 | 2.21 | 3.77 | 3.23 | 2.44 | 4.18 | 3.94 | 1.61 |
Current Ratio |
4.96 | 2.83 | 2.72 | 2.37 | 3.89 | 3.35 | 2.80 | 4.33 | 4.13 | 1.76 |
Net Debt/EBITDA |
49.29 | 24.02 | (30.36) | 1.45 | 1.87 | 1.96 | 1.09 | 3.04 | 6.32 | 1.28 |
Debt/Assets |
5.31% | 6.50% | 6.20% | 5.15% | 29.93% | 8.44% | 13.69% | 5.75% | 6.15% | 13.66% |
Debt/Equity |
0.07 | 0.11 | 0.11 | 0.08 | 0.40 | 0.12 | 0.20 | 0.07 | 0.08 | 0.23 |
Asset Turnover |
0.36 | 0.49 | 0.73 | 0.36 | 0.34 | 0.38 | 0.41 | 0.38 | 0.51 | 0.76 |
Operating CF/Net income |
(0.14) | 0.01 | 2.18 | 0.74 | 1.05 | 0.49 | 0.76 | 0.44 | 0.33 | (0.82) |
Capex/Depreciation |
(1.81) | (1.45) | (3.97) | (4.23) | (2.33) | (3.23) | (1.73) | (1.77) | (1.95) | (1.85) |
Interest Coverage |
(13.67) | (15.22) | 24.21 | (625.30) | (554.59) | (249.90) | (142.12) | (91.81) | (36.71) | (28.63) |
| 45.17% | 4.98% | 14.60% | (43.05%) | (24.98%) | (30.23%) | (29.24%) | (16.67%) | (7.76%) | 7.64% | |
| 30.19% | 2.95% | 8.73% | (30.04%) | (18.57%) | (21.14%) | (21.26%) | (13.24%) | (5.69%) | 4.09% | |
ROIC |
0.00% | (147.26%) | 0.00% | (432.48%) | (46.78%) | (84.84%) | (57.40%) | (40.81%) | (20.43%) | (19.83%) |
Return on Tangible Assets |
33.94% | 4.82% | 12.70% | (64.21%) | (20.67%) | (31.71%) | (47.17%) | (24.80%) | (7.82%) | 14.23% |
Average Days of Receivables |
98.83 | 99.70 | 57.40 | 129.43 | 168.72 | 121.36 | 105.15 | 96.13 | 81.06 | 83.36 |
Research and Development Expense of Revenue |
27.04% | 33.66% | 36.04% | 90.73% | 83.98% | 76.66% | 67.45% | 53.32% | 31.31% | 30.95% |
Selling, General and Administrative Expense of Revenue |
18.78% | 17.92% | 15.89% | 31.92% | 35.70% | 26.91% | 25.84% | 22.72% | 17.94% | 18.32% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.05 | 0.07 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
2.79% | 3.43% | 4.37% | 7.17% | 11.79% | 8.62% | 5.66% | 4.73% | 1.96% | 1.59% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(22.07%) | (20.42%) | (16.80%) | (33.39%) | (6.90%) | (5.72%) | (7.73%) | (5.12%) | (0.10%) | (2.06%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
3.20 | 3.68 | 4.93 | 2.52 | 2.25 | 1.63 | 1.54 | 1.61 | 1.95 | 1.81 |
Operating CF per Share |
(0.38) | 0.00 | 1.29 | (1.59) | (1.29) | (0.44) | (0.61) | (0.25) | (0.07) | (0.08) |
Capex per Share |
(0.14) | (0.10) | (0.19) | (0.22) | (0.11) | (0.14) | (0.06) | (0.05) | (0.04) | (0.04) |
Free Cash Flow per Share |
(0.52) | (0.10) | 1.10 | (1.80) | (1.39) | (0.58) | (0.67) | (0.30) | (0.11) | (0.12) |
Cash per Share |
7.97 | 4.89 | 5.22 | 3.72 | 6.38 | 3.12 | 1.63 | 2.27 | 2.90 | 0.87 |
Shareholders Equity per Share |
7.29 | 4.51 | 4.37 | 3.76 | 6.56 | 3.72 | 2.35 | 3.10 | 3.93 | 1.71 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.29 | 4.51 | 4.37 | 3.76 | 6.56 | 3.72 | 2.35 | 3.10 | 3.93 | 1.71 |
Free Cash Flow |
(88.78) | (17.44) | 186.65 | (305.26) | (220.98) | (81.65) | (89.48) | (39.21) | (13.96) | (13.90) |
Working Capital |
1,251.57 | 689.99 | 693.81 | 485.99 | 900.42 | 372.34 | 203.92 | 285.06 | 327.60 | 72.26 |
Capital Expenditures |
(24.12) | (17.93) | (32.61) | (36.66) | (16.76) | (19.58) | (8.56) | (6.36) | (5.02) | (4.33) |
Net Current Asset Value |
1,065.51 | 564.21 | 560.45 | 447.31 | 878.93 | 325.57 | 164.80 | 250.68 | 319.23 | 29.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.09 | 0.05 | 0.09 | 0.04 | 0.03 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.13 | 0.08 | 0.11 | 0.17 | 0.25 | 0.24 | 0.22 | 0.18 | 0.24 |
Cash ROIC |
(3.27%) | (1.03%) | 10.92% | (23.11%) | (8.98%) | (8.04%) | (15.07%) | (5.27%) | (1.59%) | (3.92%) |
Accounts Receivable Turnover |
3.42 | 4.15 | 5.92 | 2.70 | 2.96 | 3.38 | 3.55 | 3.89 | 4.69 | 4.92 |
Accounts Payable Turnover |
7.64 | 8.85 | 7.16 | 5.54 | 7.10 | 6.78 | 6.46 | 5.76 | 5.87 | 5.24 |
Inventory Turnover |
7.35 | 6.93 | 7.19 | 6.73 | 9.30 | 10.48 | 11.23 | 11.95 | 14.29 | 13.97 |
Average Days of Payables |
49.41 | 44.49 | 34.49 | 83.44 | 58.20 | 61.21 | 54.61 | 64.98 | 50.58 | 82.98 |
Days of Inventory on Hand |
44.63 | 52.73 | 47.72 | 66.51 | 50.54 | 38.27 | 36.94 | 31.21 | 24.47 | 29.94 |
Average Receivables |
160.33 | 151.96 | 141.49 | 157.91 | 120.21 | 67.41 | 57.71 | 54.98 | 51.46 | 43.91 |
Average Payables |
44.03 | 39.42 | 53.72 | 56.15 | 36.39 | 27.79 | 24.79 | 25.00 | 29.95 | 29.81 |
Average Inventory |
45.76 | 50.33 | 53.47 | 46.22 | 27.76 | 17.99 | 14.26 | 12.05 | 12.31 | 11.19 |
Average Assets |
1,513.65 | 1,276.98 | 1,154.61 | 1,201.05 | 1,048.39 | 594.62 | 498.62 | 565.03 | 470.18 | 286.02 |
Average Common Equity |
1,011.56 | 757.62 | 690.13 | 838.19 | 779.23 | 415.93 | 362.58 | 448.61 | 344.51 | 153.17 |
Columns are period end dates